All Stories

  1. High-Touch, High-Risk: An Exploratory Microbiome Analysis of Hospital Wheelchairs
  2. Epidemiology and Molecular Characterization of Mycoplasmosis in Northeastern Part of Italy, 2023
  3. Post-Translational Modifications in Respiratory Virus Infection: Recent Insights into the Development of In Vitro Models
  4. Evaluation of Biocontrol Measures to Reduce Bacterial Load and Healthcare-Associated Infections
  5. MALAT1 Expression Is Deregulated in miR-34a Knockout Cell Lines
  6. Exploring the Interplay of RUNX2 and CXCR4 in Melanoma Progression
  7. Advanced Cellular Models for Rare Disease Study: Exploring Neural, Muscle and Skeletal Organoids
  8. Efficiency of Chitosan Nanocarriers in Vaccinology for Mucosal Immunization
  9. Editorial: Nanomaterials for the diagnosis and therapy of viral infections
  10. Increased Prevalence of Unstable HLA-C Variants in HIV-1 Rapid-Progressor Patients
  11. Antibody response to BTN162b2 mRNA vaccination in naïve versus SARS-CoV-2 infected subjects with and without waning immunity
  12. Control of the Autophagy Pathway in Osteoarthritis: Key Regulators, Therapeutic Targets and Therapeutic Strategies
  13. SARS-CoV-2 Vaccination Elicits Unconventional IgM Specific Responses in Naïve and Previously COVID19-Infected Individuals
  14. Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?
  15. ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19
  16. The Emerging Role of the RBM20 and PTBP1 Ribonucleoproteins in Heart Development and Cardiovascular Diseases
  17. Benzodiazepine Use and HIV-Associated Neurocognitive Impairment: Which Comes First?
  18. A Potential Role of RUNX2- RUNT Domain in Modulating the Expression of Genes Involved in Bone Metastases: An In Vitro Study with Melanoma Cells
  19. Molecular and Lifestyle Factors Modulating Obesity Disease
  20. NF-κB and MicroRNA Deregulation Mediated by HTLV-1 Tax and HBZ
  21. CRISPR/Cas system: An emerging technology in stem cell research
  22. Interferon gamma inducible protein 16 (IFI16) expression is reduced in mantle cell lymphoma
  23. Physical Activity Prevents Cartilage Degradation: A Metabolomics Study Pinpoints the Involvement of Vitamin B6
  24. TRAF3 Is Required for NF-κB Pathway Activation Mediated by HTLV Tax Proteins
  25. Runx2 stimulates neoangiogenesis through the Runt domain in melanoma
  26. Inflammation and Metabolism in Cancer Cell—Mitochondria Key Player
  27. Inflammation in Cancer: Part of the Problem or Part of the Solution?
  28. RNA-binding proteins RBM20 and PTBP1 regulate the alternative splicing of FHOD3
  29. HIV-1-Associated Neurocognitive Disorders: Is HLA-C Binding Stability to β2-Microglobulin a Missing Piece of the Pathogenetic Puzzle?
  30. Correction for Parolini et al., “Stability and Expression Levels of HLA-C on the Cell Membrane Modulate HIV-1 Infectivity”
  31. Erratum: Corrigendum: HIV-1 Env associates with HLA-C free-chains at the cell membrane modulating viral infectivity
  32. HTLV Deregulation of the NF-κB Pathway: An Update on Tax and Antisense Proteins Role
  33. HLA-C stabiliy modulates HIV-1 infectivity
  34. IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia
  35. HIV-1 Env associates with HLA-C free-chains at the cell membrane modulating viral infectivity
  36. Molecular characterization of HIV-1 Nef and ACOT8 interaction: insights from in silico structural predictions and in vitro functional assays
  37. Comment on "Influence of HLA-C Expression Level on HIV Control"
  38. Gelsolin activity controls efficient early HIV-1 infection
  39. HLA-C and HIV-1: friends or foes?
  40. C3 HIV-1 Env and HLA-C
  41. 157a HLA-C Associates with Env and Increases HIV-1 Infectivity
  42. HLA-C is necessary for optimal human immunodeficiency virus type 1 infection of human peripheral blood CD4 lymphocytes
  43. Unsung Hero Robert C. Gallo
  44. Analysis of colorectal cancers for human cytomegalovirus presence
  45. HLA-C increases HIV-1 infectivity and is associated with gp120
  46. Induction of human immunodeficiency virus neutralizing antibodies using fusion complexes
  47. Coinfection With HIV-1 and Human T-Cell Lymphotropic Virus Type II in Intravenous Drug Users Is Associated With Delayed Progression to AIDS
  48. New vaccine strategies for chronic viral infections
  49. Kinetics of transcription of human cytomegalovirus chemokine receptor US28 in different cell types.
  50. Chemokine Sequestration by Viral Chemoreceptors as a Novel Viral Escape Strategy: Withdrawal of Chemokines from the Environment of Cytomegalovirus-infected Cells
  51. Short Communication: Geographic and Demographic Differences in the Frequency of Human Cytomegalovirus gB Genotypes 1–4 in Immunocompromised Patients
  52. Quantitation Of Human Cytomegalovirus DNA From Peripheral Blood Cells Of Human Immunodeficiency Virus-Infected Patients Could Predict Cytomegalovirus Retinitis
  53. Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study Group.
  54. Quantification of human cytomegalovirus DNA in peripheral blood polymorphonuclear leukocytes of immunocompromised patients by the polymerase chain reaction
  55. Identification of a human cytomegalovirus mutant in the pp150 matrix phosphoprotein gene with a growth-defective phenotype
  56. Human Cytomegalovirus Infection of the Major Leukocyte Subpopulations and Evidence for Initial Viral Replication in Polymorphonuclear Leukocytes from Viremic Patients
  57. Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leuckocytes from AIDS patients with human cytomegalovirus viraemia
  58. Monitoring of Human Cytomegalovirus Infections and Ganciclovir Treatment in Heart Transplant Recipients by Determination of Viremia, Antigenemia, and DNAemia